CDC42 effector protein 1Genealiases: BORG5 · CEP1 · MSE55
Q-omics provides the consensus-scored CDC42EP1 profile across patient tissues and cancer cell-line models. CDC42EP1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, CDC42EP1 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, CDC42EP1 protein abundance shows 25,234 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight COAD, THCA, and PDAC as cancer lineages where CDC42EP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDC42EP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDC42EP1 survival associations across molecular data types. CDC42EP1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDC42EP1 RNA expression–survival associations across cancer types. High CDC42EP1 expression shows unfavorable associations in COAD, BLCA, BRCA and SKCM, but favorable associations in UVM and DLBC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for CDC42EP1 RNA expression.
This table summarizes CDC42EP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CDC42EP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDC42EP1 shows lower tumor expression in UCEC and higher tumor expression in THCA, COAD, KIRP, LIHC and HNSC. The THCA box plot shows higher CDC42EP1 RNA expression in tumor versus normal tissue (log2 FC = +1.547, t-test p < 0.001).
This table shows molecular features associated with CDC42EP1 in patient tissues and cancer cell lines. In patient samples, CDC42EP1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, CDC42EP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
